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Membrane-anchored proteins have essential roles in living 
systems as enzymes, inhibitors, scaffolding proteins, signalling 
proteins, complement regulatory proteins or antigens. Covalent 
modifications of these proteins include the addition of a 
myristoyl, palmitoyl, prenyl or glycosylphosphatidylinositol 
(GPI) moiety,1 and the resulting lipoproteins are anchored to 
biological membranes via hydrophobic interactions between 
these lipid chains and the lipid bilayers of the cell. GPI-anchored 
proteins (GPI-APs) are among the most-investigated membrane-
associated proteins, because of their unexplored functions which 
might be related to several diseases such as paroxysmal nocturnal 
hemoglobinuria, prion diseases, carcinogenesis or sleeping 
sickness.2 The complex structure of the GPI glycolipids has 
inspired the preparation of several simplified membrane anchors 
that were applied in biophysical studies.3-5 In order to introduce 
functional proteins into membranes, isolated GPI-APs were 
investigated and were found to retain the biological function after 
re-insertion into membranes.6 Moreover, proteins fused with GPI 
signal sequences were found to be membrane-anchored and 
functional after in vivo posttranslational replacement of the GPI 
signal sequence with a GPI moiety.7 Based on these features, 
GPI-APs, engineered GPI-APs and their simplified semisynthetic 
analogues are potential candidates for cell surface presentation of 
proteins. 
If semisynthetic lipoproteins are to be anchored to the plasma 
membrane for the investigation of their physical or biological 
properties, their exogenous introduction requires both pure 
lipoproteins lacking surplus lipids over the stoichiometric anchor 
lipid and a mild membrane delivery method compatible with live 
cell applications.4,8 The amphiphilic nature of lipoproteins, 
however, denotes an inherent difficulty. Preventing their 
denaturation often requires the application of detergents5,9 or lipid 
species that solubilize lipoproteins via the formation of mixed 
micelles. During cell membrane delivery the lipoprotein and 
these additional amphiphiles co-associate with the plasma 
membrane, and thus, contaminate it. Recently we have shown 
that cholesterol can be applied as a protein membrane anchor and 
in the form of β-cyclodextrin inclusion complex, the cholesteryl 
lipoprotein can be purified and delivered to the plasma membrane 
of live cells without membrane perturbing agents.8 This finding 
inspired us to use cholesterol derivatives for introducing a 
bioorthogonal functionality to the cell membrane. In this way 
biomolecules containing complementary functionality can be 
directly conjugated to the headgroup of the cholesterol moiety 
that is pre-incorporated into the outer leaflet of the cell 
membrane. In our method an amphiphilic cholesterol containing 
an azide in the headgroup was delivered to the plasma membrane 
and then a protein equipped with a fluorescent alkyne tag was 
conjugated via a copper-catalyzed azide-alkyne cycloaddition 
(CuAAC).10,11 The ligand-accelerated CuAAC reaction is rapid 
and chemoselective between azides and alkynes, however, the in 
situ preparation of the effective Cu(I) catalyst11 generates reactive 
oxygen species that provides oxidative stress and induces protein 
degradation.12 Accelerator ligands (e.g. tris(triazolylmethyl)-
amines, His) were developed to decrease this drawback as they 
were reported to maintain the effectiveness of the catalytic 
copper complex and the reducing agent at low concentrations, 
and their application could shorten the reaction time to 10 
min.13,14 In the presence of His, longer reaction times were 
necessary, but its lower toxicity makes the slower reaction 
feasible and finally resulted in higher conversion. In another 
approach, copper-free click reactions were utilized to eliminate 
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Cholesteryl lipoprotein semisynthesis was accomplished via a copper-catalyzed azide-alkyne 
cycloaddition on the surface of live cells. In this convergent synthesis an azido-cholesterol was 
introduced into the cell membrane without the application of detergents followed by conjugation 
of the C-terminal alkyne modified protein. This cytocompatible method resulted in a folded 
membrane-anchored protein containing a small molecule fluorophore in the lipid headgroup. 




Figure 1. Cell surface preparation of cholesteryl-mCherry. (a) Cells were treated with azido-cholesterol – β-cyclodextrin inclusion complex (30 µM) in serum 
free medium, RT, 30 min; (b) 5 eq. 3, 20 mM Tris, 10 mM TCEP, pH 7.5, RT, 1 h. Azido-cholesterol pre-treated cells were incubated with (c) 60 µM mCherry-3 
or with (d) 30 µM 3 in the presence of 50 µM CuSO4, 500 µM NaAsc, 100 µM His and 500 µM aminoguanidine in PBS, pH 7.4, 30 min. FL represents 
fluoresceine. 
the cytotoxic effects of copper.15 The reactive compounds in 
these reactions, however, could participate in nonspecific 
conjugations with thiols in Cys containing proteins. Furthermore, 
the complicated synthesis of such reagents (e.g. tetrazines, trans-
cyclooctynes) inhibits their widespread applications in 
bioconjugation.16 Beyond the high reaction rate and 
chemoselectivity, the advantages of the CuAAC reaction for our 
purpose includes the hydrolytic and enzymatic stability of azides, 
alkynes, and the triazole product formed in the headgroup of the 
cholesterol anchor in live cell cultures.14,17 
In our semisynthetic strategy C-terminal protein cholestery-
lation was achieved by modification of the C-terminus with an 
alkyne tag followed by a CuAAC reaction with a membrane-
incorporated azido-cholesterol (Figure 1). The procedure was 
demonstrated by the cell surface conjugation of the red 
fluorescent protein mCherry. The fluorescence of this model 
protein is sensitive to structural changes, thus, is indicative about 
the retention of the native protein structure after lipidation, and 
further, can be directly imaged on the cell surface. A fluorescein 
labelled propargylglycine (Pra) derivative was applied as the C-
terminal alkyne tag, and accordingly a dual fluorescent protein 
was obtained that was found to be advantageous to demonstrate 
the presence of both the protein and the linker moiety on the cell 
surface. 
The azido-cholesterol derivative was prepared by N-acylation 
of 1-amino-11-azido-3,6,9-trioxaundecane with cholesterol 
hemisuccinate as earlier reported.8 In this lipid, cholesterol is 
linked to the polar di(ethylene glycol) spacer via an ester group 
that was found to be resistant against hydrolysis under 
physiological conditions. The polar oligoether spacer provides 
hydrophilic character to the headgroup and assists in exposing 
the azide group toward the extracellular space which is required 
for the cell surface CuAAC reaction. 
C-Terminal tagging of the model protein was achieved via the 
Michael addition of the Cys-extended mCherry-Cys protein and a 
maleimido alkyne. In order to prepare fluorescein labelled 
maleimido alkynes, Fmoc-Pra-OH was used as a starting material 
that was transformed in two ways (Scheme 1). In the first 
strategy, N-(2-aminoethyl)maleimide was N-acylated with Fmoc-
Pra-OH in the presence of HOBt, EDC and DIEA. Next, the Nα-
Fmoc deprotection of 1 was investigated under different 
conditions (For details see ESI Table S1). This was found to be a 
difficult step, because under basic conditions both the secondary 
amine deprotecting agents and the resulting amine 2 were 
sufficiently nucleophilic to give Michael adducts with the 
maleimido-alkyne.18 The Fmoc protecting group could be cleaved 
under neutral condition using tetrabutylammonium fluoride 
(TBAF),19 however, this resulted in 2 being obtained in low 
isolated yield. When piperidine was used (7.5 eq., DMF, 5 min) 
the concurrent Michael addition was found to be very fast and the 
piperidine adduct of 2 was obtained. Under milder conditions 




Scheme 1. Preparation of fluorescent alkynes. (a) 1 eq. HOBt, 1 eq. DIC, 1 eq. DIEA, THF, RT, 8 h, 90%; (b) 1.7 eq. TBAF, DMF, RT, 1 h, 38%, or 3 eq. TBD-
methyl polystyrene, DMF, RT, 24 h, 44%; (c) 1.5 eq. FITC, 5.5 eq. DIEA, THF, RT, 6 h, 71%; 3 was also prepared in one pot by combining (b) and (c): 3 eq. 
TBD-methyl polystyrene, 1.5 eq. FITC, DMF, RT, 24 h, 39%; (d) 1 eq. HOBt, 1 eq. DIC, THF, 1.2 eq. 5-aminofluorescein, RT, 18 h, 40%; (e) 2%(v/v) DBU, 
MeOH, RT, 20 min, 88%; (f) 1.25 eq. DIEA, 1.25 eq. maleimidopropionic acid-OSu, DMF, RT, 3 h, 85%. 
incomplete and the piperidine adducts of 1 and 2 were formed. 
The application of sterically hindered amines, dicyclohexylamine 
and triethylamine, or bicyclic amidine bases required either a 
larger reagent excess or longer reaction time, but after complete 
Fmoc removal the intramolecular oligomeric adducts of 2 were 
obtained. The solid-supported amidine base TBD-methyl 
polystyrene was found to be the optimal cleavage agent, and 
amine 2 was obtained in higher isolated yield than in the case of 
TBAF. The formation of the intermolecular adducts of 2 was 
presumably reduced by the less basic suspension of the solid 
supported amidine as compared to the DBU solution. The filtrate 
of the reaction mixture was immediately used in the following 
step where fluorescein-isothiocyanate (FITC) was added to 2 
resulting in the formation of the fluorescent alkyne tag 3. In order 
to increase the overall yield of 3, a one-pot approach was also 
investigated. The most efficient cleavage agents TBAF and TBD-
methyl polystyrene were applied in the presence of FITC. The 
solid supported base was found to be more effective because of 
the simple work-up, and thus, the isolated yield of 3 was higher. 
The difficult preparation of the amino-maleimide intermediate 
was excluded in the second strategy. Fmoc-Pra-OH was used to 
N-acylate fluorescein amine in THF resulting in the formation of 
the protected alkyne 4. Fmoc deprotection of 4 was found to be 
quantitative in the presence of 2% DBU, and the resulting amine 
5 was N-acylated with 3-maleimidopropionic acid N-
hydroxysuccinimide ester giving the fluorescent maleimido 
alkyne 6. 
The structural differences between 3 and 6 is minimal, and it 
was found that such changes in the cholesterol anchor headgroup 
were tolerated with the retention of membrane association.20 In 
order to demonstrate the usefulness of the prepared fluorescent 
maleimido alkynes, 3 was used to tag the C-terminus of 
mCherry-Cys. Since mCherry does not contain Cys residues, the 
C-terminal Cys extension makes the chemoselective C-terminal 
modification possible via Michael addition. The conjugation 
reaction was performed with a protein to tag ratio of 1:5, and the 
total amount of 3 was added in 5 portions over 1 h. The Michael 
addition was found to be fast and the resulting mCherry–3 was 
separated from the excess of 3 by size exclusion chromatography. 
The purified conjugate was analyzed by SDS-PAGE and it was 
found that the protein alkyne did not contain surplus fluorescent 
tag 3 (Figure 2). Under denaturing conditions, the acylimine 
group of the mCherry fluorophore matured from the Met71-Tyr-
Gly73 sequence was hydrolyzed,21 resulting in the appearance of 
additional bands with a Mw of 7.8 and 19.8 kDa. The bands 
corresponding to the full length mCherry-Cys and the C-terminal 
mCherry-Cys fragment were found to be fluorescent under UV 
light revealing the covalent attachment of the fluorescein labelled 
alkyne 3 to the C-terminus of mCherry-Cys. Excitation and 
emission spectra of the conjugate also evidenced the presence of 
both fluorophores. 
In order to perform the CuAAC reaction on the surface of live 
cells, the azido-cholesterol was first introduced into the plasma 
membrane of cultured SH-SY5Y cells. β-Cyclodextrin was used 
as a delivery vector, and the corresponding inclusion complex 
was prepared by incubating 30 µM of azido-cholesterol and 75 
μM of β-cyclodextrin overnight in DMEM cell culture medium. 
The cells were then treated with the resulting solution of the 
azidolipid complex for 30 min. It is important to note, that the 
normal cellular cholesterol level was not affected by the presence 
of 75 μM β-cyclodextrin, because cholesterol extraction requires 
much higher β-cyclodextrin concentration.22 Parallel to the azido-
cholesterol loading, the copper catalyst was prepared by reducing 
CuSO4 (50 µM) with NaAsc (500 µM) in the presence of His 
(100 µM) over 15 min followed by the addition of the carbonyl 
capturing reagent aminoguanidine (500 µM). Finally, 3 or 
mCherry–3 were added. Cells were then washed and treated with 
the resulting alkyne solutions. The ligand accelerated CuAAC 
reactions performed on live cell surface were monitored by 
fluorescence microscopy (Figure 3). In control experiments cells 
were not pretreated with azido-cholesterol, but incubated with 3 
or with mCherry-3 in the presence of the same catalyst and 
additives. These experiments resulted in no detectable fluorescent 
cell labelling even when 3 or mCherry–3 was applied at 100 µM, 
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Figure 2.  (A) Coomassie blue stained (left) and fluorescence detected (right) 
15% SDS PAGE gel: lane 1, Mw marker; lane 2, mCherry–3 conjugate; lane 
3, 3. mCherry does not produce fluorescence when excited at 365 nm. (B) 
Excitation (─ λem= 518 nm; ─ λem= 610 nm) and emission (--- λex= 488 nm; --
- λex= 587 nm) spectra of 15 µM mCherry–3 in H2O at 25°C. 
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Figure 3. Confocal laser scanning and differential interference contrast (right 
bottom) images of SH-SY5Y cells. Azido-cholesterol pre-treated cells were 
incubated with 3 or with mCherry–3 in DMEM in the presence of 50 µM 
CuSO4, 500 µM NaAsc, 100 µM His and 500 µM aminoguanidine for 30 
min. In control experiments SH-SY5Y cells were not pre-treated with azido-
cholesterol. On the images fluorescein is green, mCherry is red and nuclei are 
blue, scale bars: 50 µm. 
and thus, evidenced that neither 3 nor mCherry-3 had non-
specific adsorption on the surface of SH-SY5Y cells. When cells 
pretreated with the β-cyclodextrin inclusion complex of azido-
cholesterol were incubated with 3, intensive green membrane 
fluorescence was observed indicating successful cell surface 
CuAAC between the cholesterol azide and 3. When the azido-
cholesterol-loaded cells were incubated with the dual fluorescent 
mCherry–3 conjugate, intensive red and green fluorescence were 
detected on the cell surface. This indicated that the mCherry 
protein C-terminally tagged with the fluorescent alkyne 3 was 
covalently attached to the headgroup of the azido-cholesterol, and 
that the cholesterol moiety of the resulting cholesteryl lipoprotein 
was able to anchor the attached protein to the plasma membrane. 
The red fluorescence of the anchored mCherry protein was also 
indicative that the cell surface cholesteryl lipoprotein formation 
did not denature the protein. 
In order to evaluate the practical usefulness of the cell surface 
semisynthesis of cholesteryl lipoproteins, the in vitro cytotoxic 
effects of the reactants were investigated in an XTT colorimetric 
viability assay 24 h and 48 h after the treatment of SH-SY5Y 
cells. It was found that the azido-cholesterol pretreatment did not 
influence cell viability, but the catalyst system alone was found 
 
Figure 4. Effects of the cell surface protein conjugation on the viability of 
SH-SY5Y cells. The XTT colorimetric assay was performed 24 h and 48 h 
after the treatments; control cells were incubated in medium only. The data 
are mean ± s.d. (n= 3–6); **P<0.01, NS, not significant P>0.05 according to 
Dunnett’s multiple comparison test, one-way ANOVA. 
to be moderately cytotoxic (Figures 4 and S1). However, both 3 
and mCherry-3 dose-dependently rescued cells from the catalyst 
induced cell death, probably via partially chelating the toxic 
copper ions. The cell surface CuAAC reaction of mCherry-3 and 
azido-cholesterol-loaded SH-SY5Y cells resulted in a viability 
loss of 2% and 17% 24 h and 48 h after the cell surface 
modification, respectively. This negligible cytotoxicity of the 
reported procedure proved that the method is practically usable. 
Conclusion 
A semisynthetic method was developed for the cell surface 
introduction of lipoproteins. Our convergent strategy includes the 
C-terminal tagging of recombinant proteins with fluorescent 
alkynes, and the simple preparation and cell membrane loading 
of amphiphilic azido-cholesterols. The ligand accelerated 
CuAAC reaction performed on the surface of live cells resulted 
in a cholesteryl lipoprotein that contained a small molecule 
fluorophore in the headgroup. Since surplus detergents or 
unreacted fluorescent lipids were not introduced into the plasma 
membrane, the fluorescent signal is unambiguously associated 
with the membrane-anchored protein. This feature makes the 
semisynthetic lipoprotein appropriate for immediate imaging 
studies. The method was demonstrated with the membrane-
anchoring of the red fluorescent protein mCherry C-terminally 
tagged with a green fluorophore containing Pra derivative. The 
application of His and aminoguanidine in the CuAAC reaction, 
and the presence of a protein alkyne in a concentration 
comparable with the copper concentration protected the SH-
SY5Y cells from the cytotoxic effects of the catalyst system, and 
under these conditions the mCherry protein was not significantly 
denatured. The reported fast and live cell-compatible CuAAC 
reaction is a mild, non-genetic method for introducing proteins or 
other molecules to the surface of cells or other membrane species 
via a cholesterol anchor. Since cholesterol is a major constituent 
of lipid rafts, that is the accumulation platform of GPI-APs,23 the 
reported strategy is adequate for mimicking the protein anchoring 
function of GPIs in further applications. 
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